Table 3 Important Anti-Tumor nanomedicines
From: Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy
Entry | Drug Name | Platform | API | Cancer | Approved Countries | References |
|---|---|---|---|---|---|---|
1 | SMANCS | Polymer conjugate | Neocarzinostatin | Hepatoma | Japan | |
2 | Doxil® | Liposome | Doxorubicin | Ovarian Carcinoma, Breast Cancer, etc. | USA | [126] |
3 | Denileukin diftitox/ Ontak® | Fusion protein | Diphtheria toxin | Cutaneous T-cell Lymphoma | USA | |
4 | Zevalin®/ Ibritumomab Tiuxetan | ADC (Anti-CD20 antibody) | Yttrium-90 | Non-Hodgkin’s lymphoma | USA | |
5 | Abraxane/nab®-Paclitaxel | Albumin-bound nanoparticle | Paclitaxel | Metastatic Breast Cancer, Advanced Non-Small Cell Lung Cancer | USA | |
6 | Genexol-PM | Polymeric micelle | Paclitaxel | Breast Cancer, Non-Small Cell Lung Cancer | USA | [137] |
7 | Onyvide | Liposome | Irinotecan | Pancreatic Cancer | USA | [138] |
8 | Mylotarg® | ADC (Anti-CD33 antibody) | Calicheamicin | Acute Myeloid Leukemia | USA | [139] |
9 | Hensify® | Nanoparticle | Hafnium oxide | Soft Tissue Sarcoma | USA |